trending Market Intelligence /marketintelligence/en/news-insights/trending/nw8jrntapveptqopm2q-kw2 content esgSubNav
In This List

Editas Medicine appoints former Patheon CEO as chairman

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms

Blog

Infographic 2022 Top Tech Trends Shaping Corporations


Editas Medicine appoints former Patheon CEO as chairman

Editas Medicine, Inc. appointed James Mullen as board chairman, effective March 28.

Mullen previously served as CEO of Patheon NV until the company's acquisition by Thermo Fisher Scientific Inc.

In addition, the Cambridge, Mass.-based biotechnology company said its co-founder Alexis Borisy and John Mendlein stepped down from the company's board.

Borisy joined the board in 2013. Mendlein, who is Moderna Therapeutics Inc.'s president of corporate and product strategy, joined Editas' board in 2016.